Life Sciences
Nishimura & Asahi advises life science and healthcare innovators, investors, and industry leaders on complex transactions, regulatory issues, and business challenges, utilizing its deep industry knowledge, legal expertise, and government insights to meet client needs.
Our cross-disciplinary life sciences and healthcare group delivers insightful, practical advice and sophisticated representation to clients on various types of challenges facing today’s life sciences and healthcare industry.
Our practice is unique in that it encompasses helping establish start-ups developing cutting-edge life science technologies, representing some of the world’s largest and most innovative pharmaceutical companies in complex IP disputes and high-profile M&A transactions, and advising on all types of regulatory matters.
We offer clients a full range of legal services, unique insights, and assistance at every stage of the product life cycle: from the development stage, through advising on IP-related matters, fundraising, licensing and partnership agreements, and clinical trials; the introduction stage, through assisting with regulatory approval acquisition and manufacturing, marketing, and commercialization/distribution arrangements; to the growth stage, through advising on brand protection, litigation, compliance, external and internal investigations, and various corporate transactions, such as strategic M&A and reorganization.
Our clients include manufacturers of pharmaceuticals, biotechnologies, medical devices, and diagnostic products; healthcare and nursing service providers, such as hospitals and clinics; healthcare professionals; universities; and leading trade and professional organizations. We also represent companies in the food, dietary supplement, and cosmetic fields.
With many of the members of our life sciences and healthcare group having previously served as in-house counsel and executives in global pharmaceutical and medical device companies, scientists, life science engineers, and senior regulators at government agencies such as the Ministry of Health, Labour and Welfare of Japan, they possess a remarkable degree of technical knowledge and industry familiarity.
Recent Work
-
- 2024.1
- Mental Health Technologies Co., Ltd. - Acquisition of Task Force Co., Ltd
-
- 2023.6
- Heartseed Inc. - Series D fundraising
-
- 2023.4
- ORIX Corporation - Acquisition of Dynamedic Japan Co., Ltd.
-
- 2023.3
- Lion Corporation: Acquisition of shares in MERAP Holding Corporation
-
- 2022
- BPEA EQT Pte. Ltd. - Sale of Bushu Pharmaceuticals Ltd. to KKR & Co., Inc.
-
- 2022
- Sponsors led by J-Will Partners Co., Ltd. - Investment in Nichi-Iko Pharmaceutical Co., Ltd.
-
- 2022
- ORIX Corporation: Basic agreement to acquire shares of DHC Corporation
-
- 2022
- Bain Capital Private Equity, LP: Acquisition of Scientific Solutions Business from Olympus Corporation
-
- 2022
- Japan Post Capital Co., Ltd. - Capital alliance with FiNC Technologies Inc.
-
- 2022
- Toyota Tsusho Corporation: Investment in miup Inc.
Awards & Rankings
-
One satisfied client says: "There are many experts in the firm and they are familiar with the industry so they provide us with realistic advice rather than a so-called 'critic's opinion'." Another impressed client comments: "The Nishimura & Asahi lawyers have a deep understanding of the pharmaceutical business and provide us with proposals that lead to solutions."
Chambers, Life Sciences: Japan (Asia-Pacific 2022) -
"We are very grateful for the high level of knowledge they have in the life sciences and medical industries," enthuses one interviewee, further complimenting the team’s "speedy and easy-to-understand responses." Another satisfied client reports that "their advice is very professional, understandable and practical.
Chambers, Life Sciences: Japan (Asia-Pacific 2021)
N&A Newsletters
-
Vietnam: Overview of the distribution rule and advertising regulations for medical devices
Asia
-
Vietnam: Overview of the national rule for Software of Medical Devices (SaMD)
Asia
-
Expansion of Business Sectors Subject to Investment Screening in Japan for the Purpose of Securing Stable Supply Chains
Competition Law / International Trade
Seminars
-
-
AI and product liability - where are we heading?
Paris
External Seminars
-
-
Speaking engagement: Administrative order under the Act against Unjustifiable Premiums and Misleading Representations concerning virus removal products and a provisional injunction against the order
Online
External Seminars
-
-
Speaking engagement: Arbitral case management in the digital economy
External Seminars
